ReviewJournal of anesthesia2007
Role of urotensin II and its receptor in health and disease.
Review in Journal of anesthesia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Capsanthin Attenuates Osteoporosis by Targeting the Urotensin II Receptor Pathway to Inhibit Oxidative Stress and NLRP3 Inflammasome Activation.Calcified tissue international · 2026Article
- In-vitro effects of the urotensin-II peptide and its receptor antagonists on mcf-7 breast cancer cell line.Journal of the Egyptian National Cancer Institute · 2026Article
- Low pregnancy-associated plasma protein-A and serum urotensin-II in 11-14 weeks gestation: case-control study.Revista da Associacao Medica Brasileira (1992) · 2026Article
- The effects of the urotensin-II receptor antagonist palosuran treatment on the corpora cavernosa of streptozotocin-induced diabetic rats.Asian journal of urology · 2025Article
- Article
- Urotensin 2 and Oxidative Stress Levels in Maternal Serum in Pregnancies Complicated by Intrauterine Growth Restriction.Medicina (Kaunas, Lithuania) · 2019Article
- Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019Article
- The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats.Experimental and therapeutic medicine · 2014Article
- In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Urotensin II levels in patients with chronic kidney disease and kidney transplants.Upsala journal of medical sciences · 2012Article
- Article
- Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype.Journal of clinical hypertension (Greenwich, Conn.) · 2010Article
- A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects.Naunyn-Schmiedeberg's archives of pharmacology · 2010Review
- Endothelium-derived endothelin-1.Pflugers Archiv : European journal of physiology · 2010Review
- Desensitisation of native and recombinant human urotensin-II receptors.Naunyn-Schmiedeberg's archives of pharmacology · 2009Article
- Urotensin II in cardiovascular regulation.Vascular health and risk management · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urotensin II (U-II) is currently the most potent vasoconstrictor identified. This action is brought about via activation of a G(q/11)-protein coupled receptor (UT receptor). U-II activation of the UT receptor increases inositol phosphate turnover and intracellular Ca(2+). In addition to producing vasoconstriction, dilation and ionotropic effects have also been described. There is considerable variation in the responsiveness of particular vascular beds from the same and different species, including humans. Receptors for U-II are located peripherally on vascular smooth muscle (contractile responses) and endothelial cells (dilatory responses via nitric oxide). In humans, plasma U-II is elevated in heart failure, renal failure, liver disease, and diabetes. Iontophoresis of U-II in healthy volunteers produces vasodilation (of the forearm) while in patients with heart failure or hypertension a constriction is observed. To date there is only one clinical study using a UT receptor antagonist (palosuran) in diabetic patients with macroalbuminuria. This antagonist reduced albumin excretion, probably by increasing renal blood flow. Studies in other disease conditions are eagerly awaited. In summary, the U-II / UT receptor system has clinical potential, and for the anesthesiologist, this novel peptide-receptor system may be of use in the intensive care unit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.